Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Exploratory Randomized Phase II Study of Trastuzumab Deruxtecan Versus Endocrine Therapy of Physician's Choice in Low-HER2 Expressing Hormone Receptor-positive Advanced Breast Cancer Patients

NCT06837792 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT06837792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06837792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Exploratory Randomized Phase II Study of Trastuzumab Deruxtecan Versus Endocrine Therapy of Physician's Choice in Low-HER2 Expressing Hormone Receptor-positive Advanced Breast Cancer Patients
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2023
Completion date
October 1, 2026
Enrollment
141 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor(hr)-positive, low her2 advanced breast cancer patients (her2 ihc 1+ or 2+ & ish negative)